IRCT20200621047859N2已完成1 期
Phase I clinical trial using ex vivo-expanded allogeneic donor-derived NK cells in patients with lower respiratory disease (Moderate) caused by COVID-19.
Motamed Cancer Institute0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Man or woman, aged 18-70 years
- •pneumonia that is confirmed by chest imaging (glass turbidity in High-resolution computed tomography[HRCT])
- •Laboratory confirmation of infection (NCP, Novel Coronavirus Pneumonia) with reverse polymerase chain reaction (RT-PCR) response from any diagnostic sampling source.
- •Ordinary transthoracic echocardiogram
- •Adequate kidney function, which is estimated based on glomerular filtration rate (CrCl> 60) ml / min or ml per minute / 1.73 square meters, (CrCl: Creatinine Clearance)
排除标准
- •Pregnancy or lactation
- •Infection for human immunodeficiency viruses (HIV) , hepatitis B virus (HBV) or hepatitis C virus (HCV)
- •Patients with other serious systemic diseases or malignancies
- •Inability to provide informed consent or compliance with test conditions
研究者
相似试验
招募中
不适用
Clinical study on the use of ex vivo expanded allogeneic mesenchymal stem cells for Parkinson's diseaseCTRI/2010/091/000432ADVANCED NEURO-SCIENCE ALLIES PVT. LTD#560, Bhargavi, 9th "A" Main, Indiranagar, Bangalore-560 038Karnataka (INDIA)15
招募中
不适用
Clinical study on the use of ex vivo expanded Allogenic Mesenchymal Stem Cells for Cerebral PalsyCTRI/2010/091/000435ADVANCED NEURO-SCIENCE ALLIES PVT. LTD#560, Bhargavi, 9th "A' Main, Indiranagar, Bangalore-560 038Karnataka (INDIA)15
尚未招募
1 期
atural Killer imune cells expansion for Acute Myeloid Leukemia treatment.Acute myeloid leukaemia Myelodysplastic syndrome, unspecifiedD46.9C92.0RBR-8qq5h9Hospital Israelita Albert Einstein
招募中
1 期
Phase II study of myeloablative allogeneic transplantation using pegylated G-CSF mobilised peripheral blood stem cells.Acute Graft Versus Host Disease following allogeneic peripheral blood stem cell transplant from am HLA identical sibling for a haematological malignancy.Blood - Haematological diseasesACTRN12605000460606A/Prof Geoff Hill47
进行中（未招募）
1 期
Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/refractory B-cell Acute Lymphoblastic LeukemiaCTIS2023-508420-36-00Ospedale Pediatrico Bambino Gesu'24